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Background: The purpose of the study is to evaluate the long-term clinical outcome through biochemical no
evidence of disease (bNED) rates among men with low to intermediate risk prostate cancer treated with two
different brachytherapy implant techniques: preoperative planning (PP) and real-time planning (IoP).
Methods: From June 1998 to July 2011, 1176 men with median age of 67 years and median follow-up of 47 months
underwent transperineal ultrasound-guided prostate 125I-brachytherapy using either PP (132) or IoP (1044) for
clinical T1c-T2b prostate adenocarcinoma Gleason <8 and prostate-specific antigen (PSA) <20 ng/ml. Men with
Gleason 7 received combination of brachytherapy, external beam radiation and 6-month androgen deprivation
therapy (ADT). Biological effective dose (BED) was calculated using computerized tomography (CT)-based dosimetry
1-month postimplant. Failure was determined according to the Phoenix definition.
Results: The 5- and 7-year actuarial bNED rate was 95% and 90% respectively. The 7-year actuarial bNED was 67%
for the PP group and 95% for the IoP group (P < 0.001). Multivariate Cox regression analyses identified implant
technique or BED, ADT and PSA as independent prognostic factors for biochemical failure.
Conclusions: Following our previous published results addressing the limited and disappointing outcomes of PP
method when compared to IoP based on CT dosimetry and PSA kinetics, we now confirm the long-term clinical,
bNED rates clear cut superiority of IoP implant methodology.
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Prostate brachytherapy has enjoyed an unparalleled resur-
gence in the last two decades. It represents the ultimate 3-
D conformal therapy. Reported dose escalation far exceeds
the best reported results of other radiation modalities.
Current brachytherapy results have been obtained using a
variety of planning and pre- and intra-operative calcula-
tions, of which no method was proven superior [1-3]. His-
torically, the prostate has been implanted using pre-
planning (PP) dosimetric methods [2,4], where a planning
transrectal ultrasound (TRUS) prostate volume study was
done several weeks before the procedure, a treatment plan* Correspondence: nicolam@tlvmc.gov.il
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stated.was conceived and on the day of the implant in the oper-
ating room the intraoperative patient positioning should
mimic exactly the pre-implant study 3 dimensional co-
horts. Several groups have described the potential and ob-
served disadvantages of this method [5-7]. The evolution
of TRUS and mainly the availability of sophisticated
treatment planning computers, have evolved into the in-
traoperative planning (IoP) methodology and made bet-
ter accuracy of intraoperative dosimetry and seed
placement [1,8,9]. Intuitively, many brachytherapy cen-
ters have moved to the various IoP techniques, but with
no clinical research data to substantiate this transition.
We had a unique opportunity since 1998 to compare in
a prospective manner the two implant planning methods.
Both treating physicians and the radiation physicistsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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hort analysis. Inclusion and exclusion criteria for treat-
ment eligibility as well as treatment protocols remained
unchanged during the entire period. Thus enabling us a
fair comparison of the implant methods as the only vari-
able changed along time. Previous reports of our group
dealt with early post treatment results comparison: com-
puterized tomography (CT)-based dosimetry calculations
[10], urinary morbidity [5] and early prostate-specific anti-
gen (PSA) kinetics following treatment [11]. Ultimately,
clinical outcomes such as biochemical no evidence of dis-
ease (bNED) rate are of the utmost importance therefore




The institutional review board of the Tel Aviv Sourasky
Medical Center approved this study and waived informed
consent requirements. A total of 1176 consecutive patients
with biopsy-proven prostate cancer were treated with
transperineal 125I-based permanent brachytherapy between
June1998 and July 2011 in our center. Men with Gleason
score ≤ 6, clinical stage T1–T2 and PSA < 20 ng/ml were
given 125I brachytherapy as monotherapy targeting 100%
isodose of 160 Gray (Gy). Men with Gleason score 7, of
the same stage or PSA values were given a combination of
125I brachytherapy (100% isodose of 107 Gy) and external
beam radiotherapy (EBRT), 45 Gy at a daily dose of
1.8 Gy. Androgen deprivation therapy (ADT) was given
either to reduce gland size, if gland volume was above
55–60 cc, or in all men with Gleason 7 disease treated
with combined radiation therapy. Duration of ADT ranged
from 6 to 9 months. Of the entire cohort, 132 were treated
in the initial period with the PP method, which was then
switched to the IoP methodology by which the next 1044
consecutive patients were treated. Patient selection criteria
and risk stratification for monotherapy vs. combined treat-
ment were established at the start of our program,
remained constant, and were regardless of the PP or IoP
methodology. Patients were seen at 1, 3, 6, 9, 12 months
and every 6 months thereafter. CT dosimetry, as suggested
by the American Brachytherapy Society (ABS), was ob-
tained at 1 month. Serum PSA was determined at each
visit from month 3 onwards. Biochemical failure was de-
fined using the Phoenix definition of a rise by 2 ng/mL
or more above the nadir PSA [12].
Brachytherapy planning methods
Methodology of PP and IoP techniques was described by
several authors. In brief, in the PP, well described by
Ragde and coworkers [4,13,14], a detailed ultrasound
measurement and mapping was done in the lithotomy
position some 4 to 6 weeks before operating day, andultrasound data were sent to the radiation physicist to
plan and choose the optimal dosimetry. At the day of
treatment, the physicist prepared the needles with seeds
and spacers in strict adherence to the preplan. In the op-
erating room, all patients were placed in lithotomy pos-
ition in an attempt to be identical to that placed at
measurement, and care was taken to duplicate exact po-
sitioning in order to optimize dosimetry. Only then were
needles inserted and seeds deployed according to the
preplan. The IoP methodology described in detail by
Stone, Stock and coworkers [8,9,15] bases its dosimetry
calculations in the operating room after the patient has
been positioned and needles inserted. It relies heavily on
rapid software calculations, and optimal dosimetry is de-
cided only then and executed in real-time. Identical
B&K ultrasound unit (Bruel & Kjaer 3553, Gentofte,
Denmark) was used for all patients as well as dedicated
software (Varian Medical Systems, Inc., Palo Alto, CA).
Both patient groups received the same postoperative
care (1 month α-blockers as default) and follow-up.
Dose equations
BED calculations were performed using exactly the same
equations described by Stock et al. [16]. Prostate contours
on the 1-month postimplant CT drawn by our team phys-
icists were used to calculate prostate dose–volume histo-
grams (DVH). Clinical target volume (CTV) was equal to
the planning target volume (PTV) [17]. To compare doses
between implant alone and combined implant with EBRT,
BED equations were used. The linear-quadratic model was
used to determine the BED for EBRT treatments using the
equation:
BED ¼ nd 1þ d=α=βð Þ½  ð1Þ
where n = number of fractions = 25; d = dose per fraction =
1.8 Gy; and α/β = a tissue and effect specific parameter
associated with the linear-quadratic model = 2. The equa-
tion used to calculate the BEDs for the low-dose-rate per-
manent decaying implants with 125I was:
BED ¼ R0=λð Þ 1þ R0= μþ λð Þ α=βð Þ½ f g ð2Þ
where R0 = initial dose rate of implant = (D90)(λ); λ = radio-
active decay constant = 0.693/T1/2; T1/2 = radioactive half-
life of isotope 125I = 59.8 days; μ = repair rate constant =
0.693/t1/2; and t1/2 = tissue repair half-time = 1 h.
Statistical analyses
Baseline characteristics are reported as percentage for
dichotomous variables, and as mean, standard deviation
(SD), median, range, and estimated 95% confidence
interval (CI) for continuous variables. Mann–Whitney U
test was used for comparison of two non-parametric
means; χ2 test was used for two proportions. Bivariate
Table 1 Baseline clinical characteristics of study patients
according to implant technique
Characteristics Total
sample
Implant technique P value
PP IoP
(n =1176) (n =132) (n = 1044)
Age, years
Mean (SD) 66.2 (6.5) 67.8 (5.9) 66.0 (6.5)
Median 67.0 68.0 67.0
Range 45.0–80.0 50.0–79.0 45.0–80.0
95% CI 65.9–66.6 66.8–68.8 65.6–66.4 0.002*
PSA, ng/ml
Mean (SD) 7.4 (3.1) 8.6 (3.8) 7.2 (3.0)
Median 6.7 7.6 6.6
Range 0.6–22.0 0.7–20.0 0.6–22.0
95% CI 7.2–7.6 7.9–9.2 7.1–7.4 <0.001*
PSA, n (%)
≤ 10 980 (83.3) 94 (71.2) 886 (84.9)
> 10 196 (16.7) 38 (28.8) 158 (15.1) <0.001**
Gleason score,
Mean (SD) 5.9 (0.6) 5.3 (0.8) 6.0 (0.5)
Median 6.0 5.0 6.0
Range 3.0–7.0 3.0–7.0 3.0–7.0
95% CI 5.91–5.98 5.2–5.5 5.9–6.1 <0.001*
Gleason score < 7, n (%) 1044 (88.8) 128 (97.0) 916 (87.7) 0.002**
Prostate volume, ml
Mean (SD) 38.4 (9.6) 35.0 (9.1) 38.8 (9.6)
Median 38.0 35.0 39.0
Range 10.0–74.0 13.0–57.0 10.0–74.0
95% CI 37.8–68.9 33.4–36.6 38.2–39.4 <0.001*
Clinical stage, n (%)
T1-T2a 1086 (92.3) 113 (85.6) 973 (93.2)
> T2a 56 (4.8) 14 (10.6) 42 (4.0) 0.001
**
ADT, n (%) 442 (37.6) 54 (40.9) 388 (37.2) 0.4**
EBRT, n (%) 132 (11.2) 4 (3) 128 (12.3) 0.002**
Follow-up, months
Mean (SD) 51.8 (35.1) 80.5 (43.5) 48.1 (32.1)
Median 47.0 83.0 47.0
Range 1.0–155.0 3.0–155.0 1.0–132.0
95% CI 49.7–53.8 72.9–87.9 46.2–50.1 <0.001*
*Mann–Whitney test, α < 0.05; **Chi-square test, α < 0.05.
PP, Preplanning; IoP, Intraoperative planning; PSA, Prostate-specific antigen;
ADT, Androgen deprivation therapy; EBRT, External beam radiation.
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tentially appropriate for multivariate analysis. We used
survival- analysis techniques for comparison between PP
and IoP study groups. Estimated likelihood of biochem-
ical failure was calculated for each group by the Kaplan-
Meier product limit estimation. The log-rank test was
used to compare differences between curves. Multivari-
ate Cox proportional hazards model was used to evalu-
ate the relationship between clinical and pathological
variables and biochemical failure. The independent vari-
ables were treatment technique, age, PSA levels, Gleason
score, T clinical stage, ADT, and dosimetry measures.
Adjusted hazard ratios (HR) and their 95% CI were com-
puted. All tests were two-tailed, and statistical signifi-
cance was defined as P value < 0.05. The analyses were
performed using the PASW Statistics 19.0 for Windows
(SPSS Inc., Chicago, IL).
Results
Patients’ characteristics
Characteristics of the 1176 patients comprising the cohort
are listed in Table 1. The median follow-up for the entire
cohort was 47 months (range, 1–155); the median follow-
up was 83 months (range, 3–155) for the PP group and
47 months (range, 1–132) for the IoP group. Patients who
received brachytherapy using the PP technique were
slightly older (1 year in median) with higher pretreatment
PSA levels (1 ng/ml in median) and disease stage; higher
percentage of intermediate risk group, but with lower Gleason
sum scores and with smaller prostate volume (P < 0.01).
Oncological endpoints in the entire cohort
Of all 1176 patients, 66 had evidence of biochemical re-
lapse, 38 were lost to follow-up, and 83 died of non-
prostate cancer causes. During the follow-up only one
patient died from prostate cancer. The 5- and 7-year
biochemical control rates were 95% and 90%, respect-
ively, for the entire cohort.
Characteristics used for multiple regression analyses to
correlate with biochemical failure were: age, pretreat-
ment PSA level, Gleason score, clinical T stage, adminis-
tration of neoadjuvant ADT and implant technique IoP
vs. PP. EBRT was not included since it was given only to
patients with Gleason 7.
The multivariate Cox regression analyses identified
PSA, ADT and implant technique as independent prog-
nostic factors for biochemical failure (Table 2, Model 1).
Implant technique was the strongest independent prog-
nostic factor (HR = 0.13, IoP vs. PP).
The 5- and 7-year actuarial biochemical control stratified
by implant technique was 78% and 67% for the PP group
and 99% and 95% for the IoP group, respectively (Figure 1).
The 5- and 7-year actuarial biochemical control strati-
fied by baseline PSA ≤ 10 or > 10 ng/ml was 82% and 74%or 68% and 50% (P = 0.97) for the PP group, and, 98% and
95% or 97% and 93% (P = 0.97) for the IoP group, respect-
ively (P < 0.001, between the groups).
The 5- and 7-year actuarial biochemical control strati-
fied by patients who received or did not receive ADT
was 82% and 66% or 75% and 66% (P = 0.41) for the PP
Table 2 Multivariate Cox regression analyses for biochemical failure in the entire cohort (n = 1176)
Factor Model 1 Model 2
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Age 0.99 (0.94–1.03) 0.49 1.01 (0.95–1.07) 0.78
PSA 1.09 (1.02–1.17) 0.011 1.08 (0.96–1.22) 0.22
Gleason 1.02 (0.72–1.46) 0.90 1.55 (0.73–3.27) 0.25
Clinical T stage 1.32 (0.59–2.94) 0.49 1.64 (0.48–5.55) 0.43
ADT 0.55 (0.31–0.99) 0.045 0.20 (0.07–.057) 0.002
Technique 0.13 (0.07–0.23) <0.001 -----------
BED ----------- 0.987 (0.981–0.993) <0.001
PSA, Prostate-specific antigen; ADT, Androgen deprivation therapy; BED, Biological effective dose.
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the IoP group, respectively, (Figure 2).
The difference in the postimplant dosimetry presented
as BED between the two methodologies was strikingly sig-
nificant (Table 3). Therefore, the implant technique was
replaced by BED in the multivariate Cox regression ana-
lysis, which identified ADT and BED as independent prog-
nostic factors for biochemical failure (Table 2, Model 2).
Oncological endpoints in the brachytherapy
monotherapy group
We further analyzed the cohort of patients by excluding
those who received brachytherapy combined with EBRT
leaving 1033 patients as monotherpay group (PP, 128
and IoP, 905). The difference in the postimplant dosimetric
measures between the two methodologies was also strik-Figure 1 Kaplan-Meier survival curves for patients with biochemical n
patients at risk is shown against each time interval. PP, preplanning; IoP, iningly significant (Table 3). To exclude the possibility that
higher BED values in the IoP monotherapy group were a
result of increased amounts of implanted 125I, we calcu-
lated the activity of 125I implanted per 1 cc of prostate.
The mean amount of 125I activity was 0.97 ± 0.15 mCi/cc
in the PP group compared to 0.87 ± 0.13 mCi/cc in the IoP
group (P < 0.001) indicating that the PP group received
clinically similar mCi amounts as the IoP group. The
5- and 7-year actuarial biochemical control rate in the
monotherapy group was 77% and 70% for the PP group
compared to 97% and 95% for the IoP group, respectively.
Oncological endpoints in the first 132 consecutive
patients of each group
To reduce potential bias because of differences in the
median follow-up period and the number of patientso evidence of disease (bNED) of the whole cohort. Number of
traoperative planning.
Figure 2 Kaplan-Meier survival curves for patients with biochemical no evidence of disease (bNED) of the whole cohort who did (A) or
did not (B) receive androgen deprivation therapy. Number of patients at risk is shown against each time interval. PP, preplanning; IoP,
intraoperative planning.
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from all patients (132) receiving PP and first 132 consecu-
tive patients who received IoP. This subsample analysis is
not restricted for healthier participants and minimize sys-
tematic (time- dependent confounding) bias. As shown in
Table 4, the characteristics of the groups were similar. The
multivariate Cox regression analyses in this sub-group
identified again implant technique as a strong indepen-Table 3 BED according to implant technique







n 1176 1 32 1044
BED, Gy
Mean (SD) 193 (28) 70 (20) 197 (16)
Median 195 82 196
Range 35–267 35–123 122–267
95% CI 191–195 74–86 196–198 <0.001
Brachytherapy
only
n 1033 128 905
BED, Gy
Mean (SD) 189 (25) 80 (19) 194 (13)
Median 193 82 194
Range 35–250 35–123 122–250
95% CI 187–191 73–86 193–195 <0.001
*Mann–Whitney test.
PP, Preplanning; IoP, Intraoperative planning; BED, Biological effective dose;
EBRT, External beam radiation.dent prognostic factor for biochemical failure (HR = 0.19,
95% CI 0.09-0.42).
The 5- and 7-year actuarial biochemical control rate in
this IoP sub-group was 96% and 94%, respectively, and still
was significantly higher than in the PP group (Figure 3).
When this sub-group was stratified by PSA or ADT, the
5- and 7-year actuarial biochemical control rates were
similar to those obtained by the entire IoP group.
Discussion
In the last three decades brachytherapy was shown to be
an equivalent treatment option to other well accepted
modalities [18,19]. This development was in part a result
of better ultrasonography, better seed placement includ-
ing coverage of periprostatic disease and certainly better
and faster computation capabilities permitting real-time
IoP implantation and dosimetry techniques [6]. These
improvements were stepwise achieved and the transition
from preoperative to intraoperative computation and
seed placement dosimetry calculation and on-site rectifi-
cation if necessary, were only slowly implemented [3,7].
It was less than a decade ago that Woolsey et al. wrote
that there were no published results backing up one im-
plant technique over the other [7]. Actually, most bra-
chytherapists switched to various IoP methods based on
intuition and not on evidence-produced by prospective
examination of the two. Our unique situation where the
same brachytherapy team switched from PP to IoP
methodology without changing any selection parameters
(e.g. age, prostate size, PSA values, clinical stage and
Table 4 Baseline clinical characteristics of first




Implant technique P value
PP IoP
(n =264) (n =132) (n = 132)
Age, years
Mean (SD) 67.7 (5.8) 67.9 (6.0) 67.4 (5.7)
Median 68.0 68.0 68.0
Range 50.0–83.0 50.0–83.0 52.0–78.0
95% CI 66.9–68.4 66.9–68.9 66.4–68.4 0.6*
PSA, ng/ml
Mean (SD) 8.2 (3.4) 8.6 (3.7) 7.8 (3.1)
Median 7.6 7.6 7.5
Range 0.7–20.0 0.7–20.0 0.8–17.0
95% CI 7.8–8.6 7.9–9.2 7.3–8.3 0.1*
PSA, n (%)
≤ 10 201 (76.1) 94 (71.2) 107 (81.1)
> 10 63 (23.9) 38 (28.8) 25 (18.9) 0.06**
Gleason score,
Mean (SD) 5.5 (0.9) 5.3 (0.9) 5.7 (0.8)
Median 6.0 5.0 6.0
Range 1.0–7.0 2.0–7.0 1.0–7.0
95% CI 5.4–5.6 5.1–5.4 5.6–5.8 <0.001*
Gleason score < 7, n (%) 248 (93.9) 128 (97) 120 (90.9) 0.07**
Clinical stage, n (%)
T1-T2a 225 (90.7) 113 (89.0) 112 (92.6)
> T2a 23 (9.3) 14 (11.0) 9 (7.4) 0.3
**
ADT, n (%) 112 (42.4) 54 (40.9) 58 (43.9) 0.6**
EBRT, n (%) 16 (6.1) 4 (3) 12 (9.1) 0.07**
Follow-up, months
Mean (SD) 83.3(39.6) 80.5 (43.5) 86.2 (35.2)
Median 84.0 83.0 95.5
Range 3.0–155.0 3.0–155.0 7.0–132.0
95% CI 78.5–88.1 72.9–87.9 80.2–92.3 0.4*
* Mann–Whitney test; ** Chi-square test.
PP, Preplanning; IoP, Intraoperative planning; PSA, Prostate-specific antigen
ADT, Androgen deprivation therapy; EBRT, External beam radiation.
Figure 3 Kaplan-Meier survival curves for patients with
biochemical no evidence of disease (bNED) of the first 132
consecutive patients from each group. Number of patients at risk
is shown against each time interval. PP, preplanning; IoP,
intraoperative planning.
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prospective comparison. In previous publications we
have shown that any improvement in results could not
be attributed to the learning curve [10,11], and thus our
observations are valid ones.
The use of the additional 45 Gy external radiation
among the Gleason 7 cohort of patients did not rectify
the deeds in the operating room. The comparison be-
tween the combination treatments among those treated
with PP vs. the IoP, while all received the same 45 exter-
nal boost and the short term ADT demonstrated againthe superiority of the latter. No statistical calculations
could be made due to the small number of cases in the
PP group. However, one of 4 men in the PP group re-
ceiving combination therapy did show biochemical re-
current disease, while none of the 128 men in the IoP
group did recur.
In multivariate analyses, seed placement methodology
as evidenced by prostate dosimetry parameters such as
BED was the strongest one to predict clinical PSA based
outcome.
While D90 was shown by many to be of importance
[20] and that there is a dose–response for biochemical
failure based on day 30 D90 dosimetry [21], it was never
demonstrated in a prospective comparison that the two
techniques vary so much in their clinical outcome and
that dosimetry based differences could predict outcome
results pointing to the clear superiority of IoP technique.
Potential explanations for this discrepancy in results is
the difficult task to reconstitute the exact patient and
prostate spatial position in the PP technique, as opposed
to real-time dosimetry calculation and implant in the
IoP technique. The fact that we limited ourselves in dose
calculations to CTV = PTV may in part explain results
of this comparative study. Difficulties in reconstituting
exact prostate position and shape may affect more the
dosimetric outcome in the PP since we did not allow
additional margins to prostate boundaries [17].
Evidence-based treatment algorithms regarding the in-
clusion of short term androgen deprivation in prostate
brachytherapy have not been adequately formulated and
Matzkin et al. Radiation Oncology 2013, 8:288 Page 7 of 8
http://www.ro-journal.com/content/8/1/288have been basically extrapolated from our knowledge of
their place in external beam regimens. The current ap-
preciation that ADT, be it even for several months dur-
ation bears along short and long-term side effects, puts
the role of ADT under scrutiny even more [22]. Lee’s
et al. [23] observation that implant quality is of greater
importance than ADT regarding input of biochemical
PSA based control, were seen by us even in the low to
intermediate risk patients, as the significance values of
the multivariate analysis among both the entire cohort
of men are more pronounced for the technique than for
ADT.
Our study limitation is firstly, the lack of randomization
between the two techniques. Given the fact that most bra-
chytherapists are currently using IoP modalities and will
not agree to participate in such a randomized study we be-
lieve our results are the best one could get before com-
pletely abandoning the PP practices. It should be taken
into account that the PP technique was used on 132 pa-
tients before we switched to the IoP, which may have had
influenced outcome. Although our previous reports as
well as the present analysis of the 132–132 patients
(Table 4) have not supported this notion [10,11]. Secondly,
our study lacks calculations which include an additional
margin to prostate gland, the lack of which may explain
some of the profound dosimetric differences observed be-
tween the two methodologies. Our results should be
looked at as a single center experience with perhaps some
limits in projecting results on other centers. However, the
fact that the current trend of other centers was to switch
to the IoP methodology attests to the fact that their results
were similar.
We have produced and communicated the entire gamut
of data we believe is necessary to build the case in favor of
the IoP methodology going from 30 days dosimetry sig-
nificantly better results [10], to 24 months urinary mor-
bidity similar outcomes [5], to mid-term PSA kinetics
showing quicker and more profound PSA declines [11], to
the current PSA-based clinical outcomes and far better
bNED rates.
Conclusions
Our long-term actuarial biochemical results add the ne-
cessary support to the current literature: modern intraop-
erative calculation based brachytherapy whether given as
monotherapy for low risk disease or in combination with
EBRT among Gleason 7 intermediate risk disease is an ex-
cellent treatment modality for localized low to intermedi-
ate risk prostate cancer patients.
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